Aldatu Biosciences

Aldatu has received $3M from the National Institute of Allergy and Infectious Diseases at the @NIH to create the first universal molecular diagnostic for the simultaneous detection and differentiation of all variants of #Ebolavirus and #Marburg virus. aldatu.bio/filoviruses

Thank you, @Labguru !

Aldatu Biosciences Adds Another Outbreak Disease to Pandemic Preparedness Portfolio - development of a universal, pan-lineage detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV), the causative agent of Crimean Congo Hemorrhagic Fever (CCHF). aldatu.bio/cchfv

#grants & awards ~@OntogenMedtech awarded $258k Phase I @nihseed #SBIRGrant to develop #PulmonaryEmbolism #catheter ~@MRKRTherapeutic awarded $2M #FDA #grant from to support Phase 2 #ARTEMIS Trial ~@AldatuBio awarded a $3M @sbirgov #grant from the @NIAIDFunding

aldatu.bio/careers to find out more and apply!

This month's Harvard Innovation Labs 10 for 10 list features innovations that help people enhance and plan their lives in a variety of ways — from improving outcomes for people who want to quit smoking to offering compassionate end-of-life planning. innovationlabs.harvard.edu/about/news/10-…

"You might call it an insurance policy against unknowns, because you don't have to change the design of your test in the future to compensate for changes," - Iain MacLeod, Aldatu CEO.

This #WorldAidsDay2021, as we work tirelessly to end the #COVID19 pandemic, let us not forget that there's still much to be done to end the 40-year AIDS epidemic.

We’re seeking a highly-motivated and talented Senior Research Associate to join our Assay Development team to work on developing the first universal diagnostic for Crimean-Congo hemorrhagic fever, recognized as a significant pandemic risk aldatu.bio/careers

Help Save Lives I'm participating in ResearcHERS: Women Fighting Cancer of Eastern New England to raise money for the American Cancer Society. Could you support me by making a donation? ⁦@AmericanCancer⁩ mobileacs.org/454asm

Aldatu's variant testing now differentiates 8 key variants - including the new Delta variant - in under two hours. Check out the product page aldatu.bio/variants or email change@aldatubio.com #covid #testing #change

Interested in #Biotechnology? Tune in to this week's episode of the "When Science Speaks" #podcast to get insights from @ijmacleod, Co-Founder, CEO, and Chief Scientific Officer @AldatuBio: #vaccines, #publichealth and more. bit.ly/WhenScienceSpe…

Confirmed Detection of eight (8) more genomes B.1.617.2 and two (2) community transmission of B.1.1.7 in South Africa, By Network for Genomic Surveillance in South Africa (NGS-SA), 13 May 2021

We can not believe that many of the papers highlighted by Nature were from South Africa. We would never dream to have created a network and consortium in Africa to advance global science. We feel so honored and humbled that we could help the world to face this pandemic...

. @MassDPH @MassHHS we have the capacity to help you test 1,000 #Covid samples per day for #CovidVariants. That’s every new positive case in MA tested for variants. Every day.

.@MassDPH @CDCDirector @RWalensky one of the fastest diagnostic approaches to detect and differentiate six key COVID variants. And @AldatuBio is offering free variant testing to those doing research in MA.

Calling all COVID clinical and academic researchers: Aldatu is offering FREE rapid variant testing of your positive samples to differentiate 6 key variants. Check out aldatu.bio/variants or email change@aldatudx.com

For everyone surprised by the @nytimes piece predicting the US will not reach herd immunity, here's a reminder that pathologist and entrepreneur Iain MacLeod of @AldatuBio made the same call back in February (and endured a lot of pushback for it): bit.ly/3qlykH3

As predicted in a February @statnews opinion piece (bit.ly/3qlykH3) by Aldatu’s CEO, Dr. Iain MacLeod, @nytimes reports that “Reaching ‘Herd Immunity’ Is Unlikely in the U.S.” nytimes.com/2021/05/03/hea…